

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**BADORC, et al.**

Examiner: **RAHMANI, Niloofar**

Application No.: **10/509,919**

Art Unit: **1625**

Filed: **October 4, 2004**

Title: **NOVEL 1,2,3-SUBSTITUTED INDOLIZINE DERIVATIVES, INHIBITORS  
OF FGFS, METHOD FOR MAKING SAME AND PHARMACEUTICAL  
COMPOSITIONS CONTAINING SAME**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. 1.56, 1.97 AND 1.98**

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

A concise explanation of the relevance of some or all of the items listed on the attached PTO-1449 (modified) is as follows:

Listed reference Rosseels, et al is in the French language and an English-language translation is not within the possession, custody or control of, and is not readily available to any


individual designated in 37 C.F.R. 1.56(c). Rosseels, et al discloses a series of 1-substituted 2-alkyl and 2-aryl-3-(4-dialkylaminopropoxy-substituted or unsubstituted benzoyl)-indolizines.

This Information Disclosure Statement is being filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.

The Commissioner is hereby authorized to charge the fee, pursuant to 37 C.F.R. 1.97(c) and 37 C.F.R. 1.17(p), of \$180.00, to Deposit Account No. 18-1982, upon which the undersigned is authorized to draw. The commissioner is hereby authorized to charge any underpayment, or credit any overpayment to Deposit Account 18-1982.

Respectfully submitted,

Date January 8, 2008

  
Paul R. Darkes; Reg. No. 33,862  
Attorney for Applicants

sanofi-aventis U.S. LLC  
U.S. Patent Operations  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (610) 889-8995  
Telefax (908) 231-2626

sanofi-aventis Docket No. SSL0082 US PCT